Free Trial
NASDAQ:GLSI

Greenwich LifeSciences 8/14/2024 Earnings Report

Greenwich LifeSciences logo
$10.04 +0.06 (+0.60%)
Closing price 04/28/2025 04:00 PM Eastern
Extended Trading
$10.70 +0.66 (+6.57%)
As of 04:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Greenwich LifeSciences EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.20
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Greenwich LifeSciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Greenwich LifeSciences Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Greenwich LifeSciences Earnings Headlines

HC Wainwright Issues Negative Outlook for GLSI Earnings
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
See More Greenwich LifeSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Greenwich LifeSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Greenwich LifeSciences and other key companies, straight to your email.

About Greenwich LifeSciences

Greenwich LifeSciences (NASDAQ:GLSI), a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

View Greenwich LifeSciences Profile

More Earnings Resources from MarketBeat